Fenofibrate falls under the drug class fibrates” which is commonly marketed as Fenoglide. It is an antilipemic agent that helps reduce cholesterol and other fatty substances from the body such as cholesterol and triglycerides, as these substances can build up along the walls of arteries and block the blood flow to the heart and other organs. This can cause strokes and heart attacks. This pharmaceutical medicine also helps increase HDL in the body (the good cholesterol). Fenofibrate is available orally, in the form of delayed-release capsules and tablets. It is usually prescribed once per day. Depending upon the brand, it can either be taken with food or without it. Fenofibrate should not be administered if you have an underlying kidney, liver, or gallbladder disease. It should also be avoided if you have a known hypersensitivity to this pharmaceutical medicine. Several side effects can manifest with the use of Fenofibrate, these include deranged LFTs, respiratory disease, abdominal and back pain, headache, constipation, nausea, rhinitis, muscle pain, diarrhea, pancreatitis, peptic ulcer, CNS depression, and arrhythmias. Fenofibrate was approved by the U.S. Food and Drug Administration on 11/05/2004. The use of this pharmaceutical medicine in pregnancy is controversial. Due to the lack of studies presenting the side effects this drug can cause to the fetus during pregnancy, it is best to avoid this drug unless the benefits outweigh the risks. Moreover, as this pharmaceutical medicine is secreted in breast milk, women who are taking Fenofibrate should not breastfeed during the treatment and up to 5 days after the regimen has stopped.

Fenofibrate acts by activating certain receptors in the body which induce lipoprotein lipase, augment the production of high-density lipoprotein (HDL), and decrease liver production of apolipoprotein C. All of this simultaneously helps maintain the balance of fats in the body. Fenofibrate increases lipolysis, stimulates lipoprotein lipase, and lowers apoprotein C-III via activating the peroxisome state sponsor receptor-associated alpha (PPAR). PPAR is a central receptor that affects lipid, insulin, and amino acid balance when activated. The activation of PPAR causes gene transcription and translation, which results in peroxisomes packed with hydrogen peroxide, reactive oxygen species, and hydroxyl radicals, all of which aid in lipolysis. This enhanced fatty acid metabolism process is also linked to increases in oxidative in the hepatic. Cirrhosis and liver cirrhosis hepatitis can develop as a result of this stress in rare circumstances. Fenofibrate is entirely degraded to acid by hepatic carboxylesterase. The carbocation of acids is either offers a variety of different or reduced to a benzhexol, which is then glucuronidated. UGT1A9 is involved in the glucuronidation of fenofibrate molecules. CBR1 is the main mediator of carboxylic reduction, with AKR1C1, AKR1C2, AKR1C3, and AKR1B1 playing lesser roles.

The price of Fenofibrate varies based on the manufacturer and the dose. The 145 mg medication costs $67 in the USA while the 160mg tablet costs $1.5 per tablet, averaging $45 for the tablets for 1 month. The wholesale cost also varies depending on the country of origin, manufacturing expenses, supplier prices, and other comparable considerations. Fenofibrate is sold at a variety of prices by a variety of Fenofibrate suppliers. Patient assistance programs, which provide free or subsidized drugs to low-income, jobless, or under-insured patients who meet certain criteria, are often supported by pharmaceutical companies.

The most dependable provider for this drug is PipelinePharma. One of the most difficult aspects of our business is finding a trustworthy partner. To overcome this issue and make life easier when seeking a reputable producer and supplier of Fenofibrate, refer to the Pipelinepharma website, which supports buyers in identifying dependable manufacturers and suppliers. Pipelinepharma, a business-to-business pharmaceutical licensing marketplace, connects entrepreneurs with clients quickly to help them build their enterprises.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Fenofibrate offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for Fenofibrate manufacturers and Fenofibrate suppliers that you are looking for. These also enable you to check the dossier status of Fenofibrate, and the GMP approvals of the different variants of Fenofibrate. Also, each manufacturer or supplier product description contains essential information about Fenofibrate including clinical data, stability zones, countries where Fenofibrate is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over Fenofibrate offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of making a list of product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than the Good Manufacturing Practice approvals that Fenofibrate manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Fenofibrate manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.